Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

• Hauptverfasser: Long He (Verfasst von), Qiuyu Li (Verfasst von), Yongfeng Yang (Verfasst von), Jiahao Li (Verfasst von), Wei Luo (Verfasst von), Yilan Huang (Verfasst von), Xiaoyan Zhong (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are employed extensively in the management of type 2 diabetes and obesity. However, there is a paucity of real-world data on their safety and tolerability for metabolic and nutritional adverse events in large sample populations. This study...